Pulmonologists from Sechenov University, affiliated with the Ministry of Health of the Russian Federation, are conducting research on the use of inhaled nitric oxide in the treatment of community-acquired pneumonia patients for the first time in world practice. Experts have successfully used this treatment to treat nosocomial pneumonia. This issue was told to socialbites.ca at the First Moscow State Medical University named after him. Sechenov.
Traditionally, inhaled nitric oxide is indicated in patients with hypertension and in the treatment of non-cardiogenic (i.e., not due to heart failure but due to other causes such as coronavirus or pneumonia) pulmonary edema. Additionally, inhaled nitric oxide has proven itself during the rehabilitation of patients after coronavirus infection (COVID-19). Pulmonologists at Sechenov University are evaluating inhaled nitric oxide as an antibacterial or antiviral agent for the first time.
“It is possible to achieve the so-called anti-infective effect if it is given for a short time, in high doses, in sessions. We note a positive effect in terms of the behavior of inflammatory markers; in fact, the hospital stay of patients with community-acquired pneumonia is shortened,” Sergei Avdeev, freelance pulmonologist of the Ministry of Health of the Russian Federation, professor, academician of the Russian Academy of Sciences, director of the Clinic of Pulmonology and Respiratory Medicine at Sechenov University, told socialbites.ca.
120 patients participated in the study. The research at Sechenov University was carried out thanks to the use of the Tianox device developed by the state company Rosatom. This is currently the only device in the world that produces nitric oxide from air. Previously, inhaled nitric oxide was only available in cylinders that had to be filled with gas and brought to the patient’s bedside.
The use of inhaled nitric oxide in the treatment of community-acquired pneumonia is a new method with proven clinical effectiveness and opens wide prospects for the treatment of patients with community-acquired pneumonia: it shortens the patient’s hospital stay and therefore reduces the burden. about the healthcare system.
Previously in Russia developed The first inhaler for training breathing techniques.